NCT00455039 2023-08-14
INST 0514C- Biologic Correlative Study: Trial of GW572016 in HER2 Overexpressing Breast Cancer Patients
University of New Mexico
Phase 1/2 Withdrawn
Clinical Trials
9 trialsNCT01205217 2017-06-07
ELATE
GlaxoSmithKline
Phase 2 Withdrawn
NCT01985893 2016-01-14
THOR
Berufsverband Niedergelassener GynÀkologischer Onkologen in Deutschland e.V.
Phase 2 Withdrawn
NCT00343759 2015-12-11
Presurgical Therapy With Lapatinib to Explore Molecular Determinants of Response to EGFR/erbB2 Targeted Therapy
University of Pennsylvania
Phase 2 Withdrawn
NCT00898573 2015-10-02
Lapatinib Resistance in Patients With Breast Cancer
Case Comprehensive Cancer Center
Withdrawn
NCT00682279 2015-04-17
A Phase I Study Of Oral Topotecan And Lapatinib In Subjects With Advanced Solid Tumors
GlaxoSmithKline
Phase 1 Withdrawn
NCT01557764 2013-07-04
Lapatinib With Trastuzumab in Treating Patients With HER2-Negative/HER2 Mutant Metastatic Breast Cancer
Washington University School of Medicine
Phase 2 Withdrawn
NCT01137994 2013-03-13
A Phase II, Randomized, Open-label Study of Lapatinib Plus Chemotherapy Versus Trastuzumab Plus Chemotherapy in HER2-positive and p95HER2-positive Metastatic Breast Cancer
GlaxoSmithKline
Phase 2 Withdrawn
NCT01700010 2013-01-17
Trial of Lapatinib and Weekly Paclitaxel for Advanced Urothelial Cancer
University of Michigan Rogel Cancer Center
Phase 2 Withdrawn